Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast.~Duration of the study: 1 year after initiation of prophylaxis with Emicizumab~Inclusion criteria: boys aged > 2 years, affected with severe hemophilia A with or without inhibitors~Evaluated outcomes: annual bleeding rate, days of absence from school, the need for additional facteur VIII consumption, satisfaction about the treatment and quality of life.~Tools used to assess quality of life are the Ivoirian version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version 2 (CHO-KLAT) and EQ-5D~The satisfaction of the parents will be assessed using the patients' global impression of change scale (PGIC).
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast